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httpcense.Abstract Background: Tuberculosis (TB) remains one of the major causes of death from a single
infectious agent worldwide. The rapid emergence of drug resistant mycobacteria has strengthened
the demand for rapid methods for detection of mycobacteria in clinical samples. As prevention of
tuberculosis relies on the early detection and cure of the infectious cases, current efforts are focused
upon improving the rapidity of identiﬁcation ofMycobacterium tuberculosis, allowing prompt initia-
tion of appropriate therapy. The rapid enzyme linked immunospot assay (ELISpot) method was
developed in the late 1990s based on the numbers of spots made by interferon gamma producing T
cells stimulated by culture ﬁltrate protein-10 (CFP-10) or early secretory antigenic target-6 (ESAT-
6). Therefore, a T-cell response to these antigens could in theory serve as a speciﬁcmarker ofM. tuber-
culosis infection.
Aim of the work: Is to assess the potential utility of ELISpot assay for monitoring treatment
response of pulmonary tuberculosis patients.
Patients and methods: The study was done on 30 patients diagnosed as pulmonary tuberculosis on
clinical, radiological and bacteriological bases. They were collected from Zagazig Chest Hospital and
Zagazig University Hospitals from January 2010 to January 2011. A total of 15 healthy volunteers
were enrolled in this study as control subjects. The following were performed for all patients before1747101.
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410 R.M. Nafae et al.treatment initiation: full history taking, complete clinical examination, chest X-ray, postero-anterior
and lateral views, tuberculin skin test (TST) byMantoux technique, and routine laboratory investiga-
tions. Three successive sputum samples for sputum smear Ziehl–Neelsen (Z–N) staining and sputum
collection for Mycobacterium culture on Lowenstein–Jensen media (L.J. media) were done. Collec-
tion of 2 ml heparinized blood for enzyme linked immunospot assay (ELISpot) was done. All patients
received four antituberculous drugs, isoniazid, rifampicin, pyrazinamide and ethambutol, for the ini-
tial 2 months. After 2 months of therapy; another three successive sputum samples for sputum smear
Ziehl–Neelsen (Z–N) staining and sputum collection forMycobacterium culture on Lowenstein–Jen-
senmediawere done.Collection of 2 ml heparinized blood for enzyme linked immunospot assay (ELI-
Spot) was done.
Results: The results of this study showed that all patients were complaining of cough and expecto-
ration. Tuberculin skin test was positive in 18 patients (60%). Most patients (46.6%) had moderately
advanced disease as regards the radiological extent. It was found that the median INF-c ELISpot
response to ESAT-6 was signiﬁcantly decreased after 2 months of antituberculosis therapy. The num-
ber of pre-treatment ESAT-6 ELISpot count in patients with positive tuberculin skin test was signif-
icantly higher than those with negative tuberculin skin test (P< 0.01). As regards bacillary load, a
statistical signiﬁcant difference between patients with AFB+++ and patients with (AFB+,
AFB++) as regards pre-treatment ELISpot count was recorded. Higher statistical signiﬁcant differ-
ence in patients with AFB+, AFB++ and AFB+++ pre and post treatment ESAT-6 ELISpot
count was found. It was found that the number of pre-treatment ESAT-6 ELISpot count in patients
with cavitary lesion was higher than those without cavitary lesion and the difference was highly sig-
niﬁcant (P= 0.01). As regards radiological extent, it was found that the number of pre-treatment
ESAT-6 ELISpot count in patients with far advanced disease was higher than patients with minimal
or moderately advanced disease. Also, after 2 months of therapy the number of ESAT-6 ELISpot
count in patients with far advanced disease showed more decline than patients with minimal or mod-
erately advanced disease. It was found that ELISpot assay sensitivity, speciﬁcity, positive predictive
value and negative predictive value in relation to L.J. media were 93.3%, 100%, 100% and 88.2%,
respectively.
Conclusion: ELISpot assaymay be used as a useful tool in the diagnosis of pulmonary tuberculosis.
The decrease in theM. tuberculosis-speciﬁc T cell responses following 2 months of successful antitu-
berculosis therapy may have a clinical value as a supplemental tool for the monitoring treatment
response of pulmonary tuberculosis patients.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.Introduction
The World Health Organization (WHO) estimates that more
than one-third of the World’s population is infected with
Mycobacterium tuberculosis. Even in the developed world,
tuberculosis (TB) rates are stable at best, and actually are
increasing in many areas. This is due to factors such as immi-
gration, the emergence of drug resistant TB strains, the human
immunodeﬁciency virus (HIV), and other immunosuppressive
conditions. Among them, nine million people get new cases
of active tuberculosis (TB) annually and 2–3 million people
die of TB each year [1].
Tuberculosis is caused primarily by direct inhalation of
infective droplet nuclei. Transdermal and gastrointestinal
(GI) transmission have also been reported [2]. Classic features
associated with active TB are cough, weight loss, anorexia, fe-
ver, night sweats, hemoptysis and chest pain. Classic symp-
toms are often absent particularly in patients who are
immunocompromised or elderly. Up to 20% of patients with
active TB may be asymptomatic [3].
The only conﬁrmation of TB diagnosis is the bacteriologi-
cal examination, but a suspicion of TB is frequently based
on clinical and radiological grounds [4]. The acid-fast bacilli
(AFB) smear of respiratory specimen, including sputum, in-duced sputum and bronchial washing specimen, is the essential
modality for the prompt diagnosis of pulmonary TB. How-
ever, the sensitivity of the AFB smear result is known to be
poor, varying between 30% and 70% depending on a number
of factors relating to how the test is implemented. Even though
the culture of tuberculosis bacilli is more sensitive (80–85%),
being able to detect as few as 10 bacteria per milliliter of spu-
tum, it usually takes 3–8 weeks to receive culture results [5].
Although the bacteriophage-based method for the detection
of mycobacterium tuberculosis has been found to be highly
sensitive and speciﬁc, it is a difﬁcult, laborious technique and
need very special skills [6].
Until recently, the tuberculin skin test (TST) has been used to
identify persons infected byMycobacterium tuberculosiswhoare
atahighriskof theprogression toactivedisease.Thismethodhas
several limitations especially in immunosuppressed individuals
such as HIV infected people who may reveal false negative
TST response. Furthermore, false positive TST responses are
alsopossible in casesofBacilleCalmette–Gue´rin (BCG)vaccina-
tion and/or non-tuberculosis mycobacterium (NTM) [7].
Advances in mycobacterium genomics in the late 1990s
identiﬁed the Region of Difference 1 (RD1), that encodes
two highly antigenic proteins, early secretory antigenic tar-
get-6 (ESAT-6) and culture ﬁltrate protein-10 (CFP-10) and
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terium TB[8].
Recently, a new generation of tests has been developed such
as QuantiFERON-TB, QuantiFERON-TB Gold (QFN-
GOLD) and ELISpot assay (also known as T-Spot. TB).
The basis of these tests is the detection in serum of either the
release of INF-c on stimulation of sensitized T-cell by myco-
bacterium tuberculosis antigen in vitro (QuantiFERON) using
a whole blood enzyme linked immunosorbant assay (ELISA)
or detection of the T-cells themselves (T-Spot. TB) [9].
The rapid ELISpot assay was developed in the late 1990s by
Lalvani et al. [10] who counted individual antigen speciﬁc T-
cells. T-cells from individuals with mycobacterium tuberculosis
infection become sensitized to ESAT-6 or CFP-10 in vivo;
when the T-cells re-encounter these antigens in vitro in the
overnight ELISpot assay, they release a cytokine, INF-c. By
the next morning each such T-cell gives rise to a dark spot,
which is the ’’footprint’’ of an individual mycobacterium
tuberculosis speciﬁc T-cell [10]. T-cell responses to the 1:1 com-
plex of ESAT-6 and CFP-10 were inferior to ESAT-6 alone
[11].
However the role of ELISpot assay in monitoring response
of TB treatment is less well-established [12].
Aim of the work
The aim of the study is to assess the potential utility of ELI-
Spot assay for monitoring treatment response of pulmonary
tuberculosis patients.
Patients and methods
Patients
This study was carried out on 30 patients attending Zagazig
Chest Hospital and Zagazig University Hospitals during the
period from January 2010 to January 2011. All patients were
suspected to have pulmonary tuberculosis on clinical and
radiological basis and conﬁrmed by sputum smear Ziehl–Neel-
sen (Z–N) staining and sputum culture on Lowenstein–Jensen
media. Twenty-two of patients were males and the rest were fe-
males with a mean age of 41 ± 17 years. Their ages ranged
from ﬁfteen to seventy-ﬁve years. A total of 15 healthy volun-
teers were enrolled as control subjects in this study. Eleven of
them were males and the rest were females with a mean age of
32 ± 7 years. In principle, we administered four antituberculo-
sis drugs to each patient for the initial 2 months (isoniazid, rif-
ampicin, pyrazinamide and ethambutol).The following were
performed for all patients before treatment initiation:
* Full history taking.
* Complete clinical examination.
* Chest X-ray, postero-anterior and lateral views:
Chest X-rays were used to detect cavitary lesions, associ-
ated complications and also grade radiological severity of dis-
ease as minimal, moderately advanced and far advanced [13].
* Tuberculin skin test (TST) by Mantoux technique.
* 3 successive sputum samples for sputum smear Ziehl–Neel-
sen (Z–N) staining.* Sputum collection for Mycobacterium culture on Lowen-
stein–Jensen media.
* Routine laboratory investigations including complete blood
count (CBC), fasting and postprandial blood sugar, serum
creatinine, blood urea nitrogen, SGOT, SGPT and
albumin.
* Collection of 2 ml heparinized blood for enzyme linked
immunospot assay (ELISpot).
The following were performed for all patients after 2 months
of therapy:
* 3 successive sputum samples for sputum smear Ziehl–Neel-
sen (Z–N) staining.
* Sputum collection for Mycobacterium culture on Lowen-
stein–Jensen media.
* Collection of 2 ml heparinized blood for enzyme linked
immunospot assay (ELISpot).
Specimen collection
3 successive sputum samples were obtained from each patient.
Patients were instructed to take deep breath, hold it momen-
tarily then cough vigorously into a sterile container. Specimens
were either processed at once or after being refrigerated at 2 C
for a maximum period of 2 days.
Specimen processing
(1) Decontamination and concentration of specimens
All specimens, which were likely to contain normal or tran-
sient bacterial ﬂora, were decontaminated by standard N-acet-
yl-L-cysteine-NaOH method [14]. Decontaminated and
concentrated sediment was resuspended in 2 ml of sterile 0.67
Magnesium phosphate buffer (pH 6.8) and used for sputum
smear Ziehl–Neelsen (Z-N) staining and culture on Lowen-
stein–Jensen (L.J.) methods.
(2) Microscopy
Smears were made for all the clinical specimens studied and
stained with Ziehl–Neelsen (ZN) staining method [14] for AFB
as follows:
Ziehl–Neelsen stain was prepared by using:
 Carbol fuchsin which consists of basic fuchsin, ethanol
95%, phenol (melted crystals) and distilled water.
 Decolorizer which consists of hydrochloric acid, ethanol
95%, methylene blue and distilled water.
 The stained ﬁlms were examined microscopically. The num-
ber of acid-fast bacilli was reported according to criteria
recommended by [15].
(3) Culture on Lowenstein–Jensen media (L.J.)
Principle
L.J. medium base is a relatively simple formulation that re-
quires supplementation in order to support the growth of
mycobacteria. Glycerol and egg mixture are added prior to
the inspissation process. The substances provide fatty acids
and protein required for the metabolism of mycobacteria.
The coagulation of egg albumin during sterilization provides
a solid medium for inoculation purposes. L–J medium also
Table 1 The clinical and demographic characteristics of the
patients.
Characteristic Patients
No. (N. = 30) %
Age in years
Median (range) 35 (15–75) –
Mean (±SD) 41 ± 17 –
Sex
Male 22 73.3
Female 8 26.7
Smokers 8 26.7
History of household close contact 6 20
412 R.M. Nafae et al.contains malachite green as an inhibitor to microorganisms
other than acid-fast bacilli [16].
0.5 ml of processed specimen was inoculated on two slants
of L.J. egg medium and incubated at 37 C. The slants were in-
spected every day for ﬁrst week and then weekly for 10 weeks
[17].
(4) Tuberculin skin test (TST)
For TST, 0.1 ml of tuberculin PPD, equivalent to three or
ﬁve tuberculin units (TU) of puriﬁed protein derivative solu-
tion (PPD-S) was injected intradermally into the volar aspect
of the forearm, and the transverse induration diameter was
measured 48–72 h later. The results of the test were interpreted
by hospital staff based on the patient degree of risk, according
to current guidelines [18].
(5) ELISpot assay
MTB-speciﬁc assay was performed using test – plates from
Gen-Probe Diaclone (S100813-Human IFN-gamma ELISPOT
Kit). Peripheral blood mononuclear cells (PBMC) were pre-
pared by Ficoll-Hypaque gradient centrifugations from 2 ml
of heparinized blood. Brieﬂy, 250,000 PBMC was plated on
one plate pre-coated with anti-human IFN-c antibody after
stimulation with ESAT-6 peptide (5 lg/ml ﬁnal concentra-
tion). The plate was incubated for 24 h at 37 C in a humid
atmosphere of 5% CO2. Spot-counting and analysis were per-
formed according to manual’s instruction. For each sample,
negative control sample (unstimulated) and a positive control
(stimulated with phorbol myrisate acetate (P-1585, Sigma) at
a ﬁnal concentration of 20 ng/ml and Ionomycin (I-0634, Sig-
ma) at 1 lM were included. The test was scored positive if the
average number of spot forming cells (SFCs) was higher than
the average number of SFCs in controls using ROC curve test.
The cut-off value for a positive response was 65 SFCs. Back-
ground number of spots in negative control was always less
than 10 SFCs and positive control more than 100 SFCs
(Fig. 1)[19].
Statistical analysis
Data analyzed using SPSS version 10. Qualitative data were
presented as numbers and relative percentage. Comparison be-
tween patients and control was done using Chi-Square test.Fig. 1 ELISpot well (one spot = one T cell).Comparison between the median of ELISpot of patients
and control was done using Mann–Whitney U test. Compari-
son of ELISpot in relative to other variables was done either
using Mann–Whitney U test or Kruskal–Wallis test. Compar-
ison between ELISpot pre- and after treatment was done using
Wilcoxon W test.
Validity of ELISpot test in the diagnosis of pulmonary TB
was done using receiver operating characteristic curve (Rock
curve). The validity of ELISpot test including sensitivity, spec-
iﬁcity, positive predictive value (PPV) and negative predictive
value (NPV) was calculated by comparing with the Lowen-
stein–Jensen media (L.J.).
Results
It is apparent from this table that males constituted the major-
ity of patients (73.3%) while females were only (26.7%) with a
mean of 41 ± 17 years. History of household close contact to
known tuberculosis patients was found in six patients (20%).
Regarding smoking history eight patients (26.7%) were smok-
ers. Ten patients (33.3%) had diabetes mellitus, four patients
(13.4%) had hypertension and two patients (6.7%) had rheu-
matic heart disease. As illustrated in Table 1 it was found that
the most prevalent complaints among the thirty patients were
cough and expectoration as they were found in all patientsCo-morbid disease
Diabetes mellitus 10 33.3
Hypertension 4 13.4
Rheumatic heart disease 2 6.7
Symptoms
Cough and expectoration 30 100
Hemoptysis 8 26.7
Dyspnea 6 20
Night fever and night sweats 20 66.7
Tuberculin skin test
Positive 18 60
Negative 12 40
Sputum smear AFB
+ 18 60
++ 8 26.7
+++ 4 13.3
Culture on Lowenstein–Jensen media
Positive 30 100
Negative 0 –
Table 2 Radiological ﬁndings among the studied patients.
Radiological ﬁndings Patients
No. %
Lung zone (s)
Upper 18 60
Lower 4 13.3
Upper and middle 4 13.3
Site of lesion
Right 14 46.6
Left 8 26.7
Cavitary lesion without inﬁltration 18 60
Cavitary lesion with inﬁltration 8 26.7
Inﬁltration without cavity 12 40
Radiological extent
Minimal 8 26.7
Moderately advanced 14 46.6
Table 3 ESAT-6 ELISpot count before therapy and after
2 months of therapy.
ESAT-6 ELISpot
count (INF-c SFCs)
Time of the test P-value
Before
therapy
2 months
after therapy
Median (range) 500 (35–850) 120 (30–540) 0.000
This table illustrated that the median value of ESAT-6 ELISpot
count was signiﬁcantly decreased after 2 months of therapy.
Table 4 ELISpot assay in relation to tuberculin skin test
(TST).
Tuberculin
skin test
ESAT-6 ELISpot count
Pre-treatment
ELISpot (INF-c SFCs)
median (range)
Post-treatment ELISpot
(at 2 months) (INF-c SFCs)
median (range)
Positive 680 (120–850) 200 (60–540)
P-value 0.01 0.09
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20 patients (66.7%), while hemoptysis was found in eight pa-
tients (26.7%), and dyspnea which was found in six patients
(20%). Regarding the tuberculin skin test, it was positive in
eighteen patients (60%). All thirty patients included in this
study were sputum positive smear for AFB and positive cul-
ture on L.J. media.
As illustrated in Table 2 it was found that the lesion was
more common in the upper lung zone (60%). The lesion also
was more common in the right lung (46.7%). Also, it was
found that 18 patients (60%) had cavitary lesion on radiology.
As regards radiological extent, it was found that eight patients
(26.7%) had minimal disease, fourteen patients (46.6%) had
moderately advanced disease and eight patients (26.7%) had
far advanced disease.
As illustrated in Table 4 it was found that the number of
pre-treatment ESAT-6 ELISpot count in patients with positive
tuberculin skin test was signiﬁcantly higher than those with
negative tuberculin skin test. But after 2 months of therapy,
there was no signiﬁcant difference in the number of ESAT-6
ELISpot count between patients with positive tuberculin skin
test and patients with negative tuberculin skin test.
As illustrated in Table 5 it was found that the number of
pre-treatment ESAT-6 ELISpot count in patients with
AFB+++ was higher than patients with AFB+ or
AFB++ with statistical signiﬁcance (P= 0.009). There were
a higher statistical signiﬁcant difference in patients with
AFB+, AFB++ and AFB+++ pre and post treatment
ESAT-6 ELISpot count.
As illustrated in Table 6 it was found that the number of
pre-treatment ESAT-6 ELISpot count was signiﬁcantly higherif the lesion affected more than one lung zone. Also, after
2 months of therapy there was signiﬁcant decrease in the num-
ber of ESAT-6 ELISpot count in patients with lesions affecting
more than one lung zone. It was found that the number of pre-
treatment ESAT-6 ELISpot count was signiﬁcantly higher if
the lesion was bilateral. After 2 months of therapy there was
a signiﬁcant decrease in the number of ESAT-6 ELISpot count
in patients with bilateral lesion than those with unilateral le-
sion. It was found that the number of pre-treatment ESAT-6
ELISpot count in patients with cavitary lesion was higher than
those without cavitary lesion and the difference was highly sig-
niﬁcant. However, after 2 months of therapy there was no sig-
niﬁcant difference in decline in the number of ESAT-6
ELISpot count between patients with cavitary lesion and those
without cavitary lesion.
It was found also that there was no signiﬁcant difference in
the number of pre-treatment ESAT-6 ELISpot count between
patients with inﬁltration and those without inﬁltration. Also,
after 2 months of therapy, there was no signiﬁcant difference
in decline in the number of ESAT-6 ELISpot count between
patients with inﬁltration and those without inﬁltration.
As illustrated in Table 7 it was found that the number of pre-
treatment ESAT-6 ELISpot count in patients with far advanced
disease was higher than patients withminimal ormoderately ad-
vanced disease. Also, after 2 months of therapy the number of
ESAT-6 ELISpot count in patients with far advanced disease
showed more decline than patients with minimal or moderately
advanced disease. There were high statistical signiﬁcant differ-
ences in patients with moderately advanced and far advanced
disease pre and post treatment ESAT-6 ELISpot count.
From Table 8, it was found that ELISpot assay showed sen-
sitivity of (93.3%) while its speciﬁcity was (100%) as well as its
positive predictive value was (100%) while its negative predic-
tive value was (88.2%).
Discussion
Tuberculosis (TB) remains one of the major causes of death
from a single infectious agent worldwide. Of great concern
for TB control is the emergence of drug resistance. There is
concern that they may spread around the world, stressing the
need for additional control measures, such as new diagnostics,
better drugs for treatment, and a more effective vaccine [20].
Tuberculosis also remains a major health threat, and the ra-
pid emergence of drug resistant mycobacteria has strengthened
the demand for rapid methods for the detection of mycobacte-
ria in clinical samples. As prevention of tuberculosis relies on
the early detection and cure of the infectious cases current ef-
forts are focused upon improving the rapidity of identiﬁcation
Table 5 Pre- and post-treatment ELISpot assay in relation to
quantitative acid fast bacilli (AFB).
Acid fast
bacilli (AFB)
ESAT-6 ELISpot count P-value
Pre-treatment
ELISpot
(INF-c SFCs)
median (range)
Post-treatment
ELISpot at
2 months (INF-c SFCs)
median (range)
AFB 380
(35–800)
120
(68–260)
0.002
AFB++ 400
(95–750)
140
(30–540)
0.01
AFB+++ 825*
(800–850)
280
(110–450)
0.003
P-value 0.009 0.6
* Statistical signiﬁcant difference between patients with
AFB+++ and patients with AFB+, AFB++ as regards pre-
treatment ELISpot count.
Table 7 Pre- and post-treatment ELISpot assay in relation
to radiological extent.
Radiological
extent
ESAT-6 ELISpot count P-value
Pre-treatment
ELISpot
(INF-c SFCs)
median (range)
Post-treatment
ELISpot at
2 months
(INF-c SFCs)
median (range)
Minimal 120 (35–200)* 100 (30–150) 0.67
Moderately advanced 670 (120–850) 120 (60–260) 0.001
Far advanced 750 (200–800) 300 (100–540)# 0.01
P-value 0.000 0.03
* Statistical signiﬁcant difference between patients with minimal
and patients with (moderately advanced, far advanced) as regards
pre-treatment ELISpot count.
# Statistical signiﬁcant difference between far advanced and
(minimal, moderately advanced) as regards post-treatment ELI-
Spot count.
Table 6 Pre- and post-treatment ELISpot assay in relation to
radiological ﬁndings.
Radiological ﬁndings ESAT-6 ELISpot count
Pre-treatment
ELISpot
(INF-c SFCs)
median (range)
Post-treatment
ELISpot at
2 months
(INF-c SFCs)
median (range)
Lung zone (s)
One zone 380(35–800) 120 (30–540)
More than one zone 680 (120–850) 110 (60–450)
P-value 0.027 0.02
Site of lesion
Unilateral 500 (35–850) 140 (360–450)
Bilateral 715 (200–750) 74 (30–110)
P-value 0.05 0.01
Cavitary lesion without inﬁltration
Present 680 (95–800) 200 (30–540)
Absent 135 (35–850) 112.5 (60–180)
P-value 0.01 0.09
Inﬁltration without cavity
Present 440 (35–850) 127.5 (60–540)
Absent 500 (95–800) 120 (30–450)
P-value 0.09 0.5
414 R.M. Nafae et al.of M. tuberculosis, allowing prompt initiation of appropriate
therapy [21].
Zaher [22] noted that tuberculosis is the third most impor-
tant public health problem in Egypt after bilharziasis and hep-
atitis C.
Therefore rapid and accurate diagnosis allows proper man-
agement of a disease. Current methods of the diagnosis of
tuberculosis are either time consuming or costly, therefore, a
rapid, reliable, simple and cost effective method would be
highly desirable, especially in developing countries where prev-
alence of tuberculosis is high [23].
Monitoring treatment response of pulmonary tuberculosis
patients is crucial both for the individual patient and for better
control of the spread of tuberculosis [24].Follow-up studies of smear-positive pulmonary tuberculo-
sis (TB) patients receiving short-course antituberculosis ther-
apy have shown relapse rates of 0–6% within 6–30 months
indicating that viable Mycobacterium tuberculosis complex
(MTB) may remain after treatment in some patients [25].
Methods to identify patients at risk of relapse and methods
to monitor response to treatment would be desirable. Clinical
evaluation of treatment response can be difﬁcult due to con-
current illness. Since radiographic resolution lags behind clin-
ical improvement microscopy and culture are currently the
methods used to monitor the efﬁcacy of treatment and out-
come [26].
Monitoring of treatment by smear examination is a crude
method since smear microscopy does not distinguish between
dead and live MTB, is not speciﬁc for MTB, and is insensitive,
with an analytical sensitivity estimated to be 5000–10,000 acid-
fast bacilli/ml. Sputum culture is superior to smear examina-
tion since it is more sensitive and speciﬁc. However, culturing
is time-consuming and, therefore, supplementary rapid and
sensitive monitoring methods would be advantageous [27].
The aim of this study was to assess the potential utility of
ELISpot assay as a simple, rapid and easy method for moni-
toring treatment response of pulmonary tuberculosis patients.
In the present study 26.7% of the patients were smokers
(Table 1). Alcaide et al. [28] reported cigarette smoking as an-
other risk factor for development of tuberculosis. TB can
apparently lie dormant and inactive in the lungs, but smoking
reduces the lung’s natural defenses against tuberculosis.
According to the World Health Organization (WHO), the
risk of prevalence of TB infection is more among current or
ex-smokers than non smokers. The risk of TB is more with
the duration of smoking than the number of cigarettes smoked
daily [29].
The biological basis by which smoking increases the TB risk
may be through a decreased immune response, mechanical dis-
ruption of cilia function, defects in macrophage immune re-
sponses, and/or CD4+ lymphopenia, thereby increasing the
susceptibility to pulmonary TB [30].
Smoking reduces the defences on the surface of the respira-
tory apparatus, alters the mucociliary apparatus through cell
destruction and dysfunction and reduces lysozyme A activity.
Table 8 ELISpot assay sensitivity and speciﬁcity in relation to Lowenstein–Jensen media.
P-value Negative predictive value (NPV) Positive predictive value (PPV) Speciﬁcity Sensitivity
0.000 88.2% 100% 100% 93.3% ELISpot assay
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sue in greater numbers. Smoking also produces alterations in
both natural and acquired cell immunity, affecting macro-
phages and leukocytes. It induces apoptosis in both activated
and non-activated macrophages, leading to the multiplication
of the bacilli [31].
Smoking inﬂuences the clinical progress of TB lesions.
Smokers tend to have more cavitary disease, and greater sever-
ity despite diagnostic delays similar to those among non-smok-
ers [32].
The most prevalent complaints among the thirty patients in-
cluded in the study were cough and expectoration as it was
found in all patients and the least prevalent complaint among
patients was dyspnea in 20% of them (Table 1). Seaton et al.
[33] stated that there is little speciﬁcity about symptoms of tuber-
culosis but one of the points in history which may make tuber-
culosis a possibility is gradual onset of symptoms over weeks
and months.
In the present study 60% of patients were tuberculin skin
test positive (Table 1). This was in agreement with the study
performed by Palomino et al. [34] who reported that the sensi-
tivity of the tuberculin skin test is estimated to be around just
60% in known active TB cases; so the test misses up to 40% of
people who are infected. This sensitivity decreases to as low as
30% in immuno-compromised people.
The major problem with tuberculin skin testing (TST) is
cross-reactivity with antigens in other mycobacteria, such as
theMycobacterium bovis BCG vaccine strain and environmen-
tal mycobacterial species. This cross-reactivity leads to false-
positive results and decreased positive predictive value
(PPV), especially in BCG-vaccinated persons and in areas of
high incidence of NTM disease [35].
All patients included in this studywere positive for acid fast ba-
cilli (AFB) by sputum Ziehl–Neelsen (ZN) stain and conﬁrmed by
sputum culture on Lowenstein–Jensen media (Table 1).
Gebre et al. [36] noted that the diagnosis of pulmonary
tuberculosis relies on bacteriological examination of sputum.
Microscopic examination of sputum smears for the demon-
stration of acid fast bacilli is believed to be a simple, cheap,
quick and the most practicable and effective method for devel-
oping countries [37]. Stains used are either Ziehl–Neelsen (ZN)
or the ﬂuorochrome method [38]. Smear sensitivity varies
among different investigators from 22% to 49.7% [39]. Marr-
oro et al. [40] supported continuous use of the acid-fast smear
as an aid in the diagnosis of mycobacterial infection.
Culture of sputum is more sensitive than smear examina-
tion, but it takes longer time before the result is known [41].
Cultivation ofM. tuberculosis from clinical samples is the gold
standard for the diagnosis of active TB. It can detect 100 bacil-
li/ml of sputum in comparison with 5000–10,000 bacilli/ml
needed for microscopy [42].
The radiological ﬁnding among the thirty patients included
in the study were as follows; (60%) showed cavitary lesion
without inﬁltration, (26.7%) showed cavitary lesion with inﬁl-
tration, (26.7%) had minimal disease, (46.6%) had moderatelyadvanced disease and (26.7%) had far advanced disease (Ta-
ble 2). Cegielski et al. [43] stated that cavitary lesion is a distin-
guishing feature of pulmonary TB and it is seen on chest
radiographs in about half the cases.
In contrast, Schaaf et al. [44] noted that 10–15% of patients
with conﬁrmed tuberculosis were thought to have a normal
chest radiograph. The Egyptian ministry of health (1994) re-
ported that the diagnosis of pulmonary tuberculosis must
not depend upon radiological ﬁnding. This is due to the fact
that many chest diseases can mimic tuberculosis on X-ray
and pulmonary tuberculosis may show many forms of radio-
logical abnormalities. However, the combined positive predic-
tive value of the typical symptoms and the ﬁnding of cavitary
upper-lobe inﬁltrates on chest radiographs are high [43].
In the present study, we found that the median INF-c ELI-
Spot response to ESAT-6 was signiﬁcantly decreased after
2 months of antituberculosis therapy (Table 3). So, ELISpot
assay can be used as a useful tool for monitoring treatment re-
sponse of pulmonary tuberculosis patients. In agreement with
the ﬁndings in this study, Aiken et al. [12] documented a reduc-
tion in the magnitude of the IFN-c ELISpot response to
ESAT-6 in response to antituberculosis treatment in almost
80% of patients with culture proven tuberculosis.
In another study,Carrara et al. [24] documented a decrease in
the IFN-c ELISpot response to ESAT-6 following 2 months of
antituberculosis treatment in 13 of 18 patients with culture con-
ﬁrmed TB that had a favorable response to treatment. Although
various epidemiological factors may have inﬂuenced the results
of these longitudinal studies, the most consistent ﬁnding is a
reduction in the magnitude of the IFN-c response toMTB-anti-
gens during antituberculosis treatment. However inmany cases,
this reduction does not result in a reversion of the IGRA result.
In contrast, Ferrand et al. [45] investigated the IFN-c ELI-
Spot response to ESAT-6 at presentation, during and at the
completion of antituberculosis treatment in patients with pul-
monary TB. In this study IFN-c ELISpot responses to ESAT-
6 were higher at the completion of antituberculosis treatment
than at presentation. Similarly, Ulrichs et al. [46] investigated
the IFN-c ELISpot response to ESAT-6 in 10 adult patients
with pulmonary TB prior to and 60 days after starting antitu-
berculosis treatment. In these 10 patients, the median IFN-c
ELISpot response to ESAT-6 was signiﬁcantly higher at
60 days compared to baseline IFN-c responses. This may be
explained by that low numbers of responder T-cells may favor
disease or, more likely, that these cells were sequestered at the
sites of active disease. Also, it is possible that infection withM.
tuberculosis induces energy of T-cells leading to failure of INF-
c production and that treatment of TB would lead to improved
immune function and an increase in antigen-speciﬁc IFN-c
production by T-cells [47]. But our study support an alternate
hypothesis that secretion of M. tuberculosis-speciﬁc proteins,
such as ESAT-6, requires metabolically active and viable bacil-
li and thus, INF-c-producing T-cells speciﬁc to ESAT-6 se-
lected epitopes are present at high frequency during the
active phase of bacterial replication [48]. However, after re-
416 R.M. Nafae et al.ceipt of efﬁcacious therapy, M. tuberculosis stops replicating
actively and the frequency of the T-cells speciﬁc for these epi-
topes dramatically decreases [49]. Another possible explana-
tion is that ELISpot assay measures the frequencies of
effector T-cells sensitized to ESAT-6 and CFP-10 antigens.
These cells are thought to closely correlate with antigen load,
driven by the burden of M. tuberculosis [50]. Therefore it is
not surprising that we found signiﬁcant qualitative and quan-
titative test reversion with effective therapy. It has been shown
that, in the patients with successful treatment for active TB,
the release of IFN-c is absent even after a prolonged 6-day
incubation with both ESAT-6 and CFP-10 antigens. It has
been suggested that IGRAs based on a prolonged period of
incubation with mycobacterial antigens could detect response
of central memory T-cells [45] and are more sensitive to iden-
tify past latent TB infection; on the other hand, short incuba-
tion IGRAs, such as ELISpot assay, mainly detect circulating
effector memory T-cells whose numbers correlate with recent
or ongoing active M. tuberculosis infection [51].
It was found that there was an association between the
number of pre-treatment ESAT-6 ELISpot count and presence
of cavitary lesion, the extent of the disease in the radiology and
the number of AFB (Tables 5–7). Lalvani et al. [52] reported
that INF-c-producing speciﬁc T-cells, as measured by the ELI-
Spot assay, may be directly related to bacillary load.
When comparing sensitivity of ELISpot assay with L.J.
media it was found to be (93.3%), and when comparing spec-
iﬁcity of ELISpot assay with L.J. media it was found to be
(100%) (Table 8) which was in agreement with the study per-
formed by Richeldi et al. [2] who reported that the sensitivity
of ELISpot assay ranges from 83% to 97%.
So as regards ELISpot assay sensitivity and speciﬁcity in
relation to L.J. media, it showed that positive predictive value
was 100% and negative predictive value was 88.2%. This was
in agreement with the study performed by Wang et al. [53] who
reported that PPV and NPV of ELISpot assay in detecting ac-
tive TB approached 100% and 90%, respectively, even in an
area with a high incidence of NTM disease.Conclusions
(1) ELISpot assay may be used as a useful tool in the diag-
nosis of pulmonary tuberculosis (Cut-off value for a
positive response was 65 SFCs).
(2) The decrease in the M. tuberculosis-speciﬁc T cell
responses following 2 months of successful antitubercu-
losis therapy may have a clinical value as a supplemental
tool for the monitoring treatment response of pulmon-
ary tuberculosis patients.
(3) ELISpot assay results are directly affected by the antigen
burden and subsequently the extent of tuberculosis
infection.
Recommendations
(1) ELISpot assay may be used to follow up treatment
among sputum smear negative pulmonary tuberculosis
patients.(2) A longer follow-up period after initiation of treatment
might be needed to better appreciate the effect of treat-
ment on T-cell responses, and subsequently to predict
complete cure or relapse.
(3) A study on ELISpot assay and Quantiferon TB test at
the same time should be looked for in the future.
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